-
1.发明公开公开(公告)号：US20230255968A1
公开(公告)日：2023-08-17
申请号：US18168221
申请日：2023-02-13
Applicant: AbbVie Inc. , Neurocrine Biosciences, Inc.
Inventor： Jayanthy Jayanth , Kevin C. Spence , Gregory A. McClelland , Anna V. Stepanenko , Kristof Chwalisz , Charlotte D. Owens , James W. Thomas , Jane Castelli-Haley , Keith Gordon , Michael C. Snabes , Ahmed M. Soliman , Geoff Zhang , David Metzger , Yanxia Li , Tzuchi R. Ju , Xi Shao , Oscar Antunez Flores , Rita Jain , Juki Wing-Keung Ng , Janine D. North , Hannah Palac , Paul M. Peloso
IPC: A61K31/513 , A61K9/20 , A61P5/30 , A61P15/00
CPC classification number: A61K31/513 , A61K9/2009 , A61K9/2018 , A61P5/30 , A61K9/2059 , A61P15/00 , A61K9/2027
Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
-
公开(公告)号：US09469673B2
公开(公告)日：2016-10-18
申请号：US13939873
申请日：2013-07-11
Applicant: AbbVie Inc.
Inventor： Ahmad Y. Sheikh , Moiz Diwan , Agnes E. Pal , Yuchuan Gong , Paul J. Brackemeyer , Geoff Zhang , Seble Wagaw
IPC: C07K5/083 , C07K5/12 , C07D487/04
CPC classification number: C07K5/123 , C07D487/04 , C07K5/0804
Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2θ) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.
Abstract translation: 本发明的特征在于化合物I的结晶形式。在一个实施方案中，化合物I的结晶形式在2θ（°2θ）为10.7,11.6,12.7,13.0,13.2,13.7,14.5的值的PXRD图中具有特征峰 ，18.7,19.0和19.9，在43％相对湿度下平衡后。
-
3.发明申请公开(公告)号：US20190054088A1
公开(公告)日：2019-02-21
申请号：US16105396
申请日：2018-08-20
Applicant: AbbVie Inc. , Neurocrine Biosciences, Inc.
Inventor： Jayanthy Jayanth , Kevin C. Spence , Gregory A. McClelland , Anna V. Stepanenko , Kristof Chwalisz , Charlotte D. Owens , James W. Thomas , Jane Castelli-Haley , Keith Gordon , Michael C. Snabes , Ahmed M. Soliman , Geoff Zhang , David Metzger , Yanxia Li , Tzuchi R. Ju , Xi Shao , Oscar Antunez Flores , Rita Jain , Juki Wing-Keung Ng , Janine D. North , Hannah Palac , Paul M. Peloso , Laura A. Williams
IPC: A61K31/513 , A61K9/20 , A61P15/00 , A61P5/30
Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
-
Patent Agency Ranking
公开(公告)号：US20150025024A1
公开(公告)日：2015-01-22
申请号：US14507267
申请日：2014-10-06
Applicant: AbbVie Inc.
Inventor： Yi Gao , Geoff Zhang
IPC: A61K9/10 , A61K47/32 , A61K38/06 , A61K31/4184
CPC classification number: A61K9/10 , A61K9/146 , A61K9/1635 , A61K31/4025 , A61K31/403 , A61K31/4178 , A61K31/4184 , A61K31/439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/7068 , A61K31/708 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , A61K47/32 , A61K2300/00
Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Abstract translation: 本发明的特征在于包含无定形形式的选定的HCV抑制剂的固体组合物。 在一个实施方案中，选择的HCV抑制剂配制成包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体
-
公开(公告)号：US20230183236A1
公开(公告)日：2023-06-15
申请号：US17995874
申请日：2021-04-09
Applicant: AbbVie Inc.
Inventor： Rodger F. Henry , Yi SHI , Geoff Zhang , Devalina Law
IPC: C07D471/04
CPC classification number: C07D471/04 , C07B2200/13
Abstract: Crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Venetoclax) are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
公开(公告)号：US20200262852A1
公开(公告)日：2020-08-20
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff Zhang
IPC: C07F9/09 , A61K45/06 , A61K31/6615 , C07C47/277 , C07C309/24 , C07C281/02 , C07F9/06 , A61K31/661
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US09034832B2
公开(公告)日：2015-05-19
申请号：US14507267
申请日：2014-10-06
Applicant: AbbVie Inc.
Inventor： Yi Gao , Geoff Zhang
IPC: A61K31/4184 , A61K38/06 , A61K47/32 , A61K9/10 , A61K38/05 , A61K38/07 , A61K45/06 , A61K9/14 , A61K9/16 , A61K31/403 , A61K31/4178 , A61K31/439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/7068 , A61K31/708
CPC classification number: A61K9/10 , A61K9/146 , A61K9/1635 , A61K31/4025 , A61K31/403 , A61K31/4178 , A61K31/4184 , A61K31/439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/7068 , A61K31/708 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , A61K47/32 , A61K2300/00
Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Abstract translation: 本发明的特征在于包含无定形形式的选定的HCV抑制剂的固体组合物。 在一个实施方案中，选择的HCV抑制剂配制成包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体
-
公开(公告)号：US08987214B2
公开(公告)日：2015-03-24
申请号：US14507267
申请日：2014-10-06
Applicant: AbbVie Inc.
Inventor： Yi Gao , Geoff Zhang
IPC: A61K31/4184 , A61K38/06 , A61K47/32 , A61K9/10 , A61K38/05 , A61K38/07 , A61K45/06 , A61K9/14 , A61K9/16 , A61K31/403 , A61K31/4178 , A61K31/439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/7068 , A61K31/708
Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
